Search results
- Christian Angermayer dropped out of college at 21 to co-found a biotech firm now worth $23 billion. The 43-year-old German billionaire runs his $3.5 billion family office Apeiron Investment Group. He told Insider why and how he invests in psychedelics and also shared his crypto investments.
www.businessinsider.com › investing-psychedelics-biotech-billionaire-crypto-spacs-longevity-space-christian-angermayer-2021-9Christian Angermayer is reinventing the psychedelics sector ...
Jul 9, 2019 · Christian Angermayer is an unlikely proselyte of psychedelia: The German financier didn’t drink so much as a sip of beer for the first three decades of his life. But five years ago, after careful...
People also ask
Who is Angermayer & how did he become a psychedelic entrepreneur?
What is Angermayer's first psychedelic trip?
Who is Richard Angermayer?
When did Angermayer go public?
Sep 15, 2021 · Angermayer saw his first psychedelic trip as the mental birth of (ATAI), a biotech company he founded to focus on psychedelic treatment for mental health disorders. In June, the Peter...
- Vicky Ge Huang
Jul 5, 2023 · Christian Angermayer (43) is a polymath, billionaire, entrepreneur and investor - but most importantly the driving force behind the renaissance of psychedelic drugs. Psychedelic Finance got one of the first interviews after the successful IPO of psychedelic market leader atai Life Sciences, which Christian has started in 2018.
4 days ago · Christian Angermayer invests in life sciences, fintech, AI, psychedelics and cryptocurrencies through his family office Apeiron Investment Group. He made his first millions cofounding biotech...
Feb 15, 2023 · In early 2017, Christian Angermayer, a German billionaire entrepreneur and investor, was developing his own infatuation with psychedelics.
Mar 11, 2020 · In his early 20s, he became a “junior partner” at the biotech company Ribopharma, which two professors he met while on a scholarship were involved in. This company attained one of the first core patents on a technology that is now referred to as “RNAi,” or, RNA interference.
In fact, Angermayer is sure his learnings from his psychedelic journeys are part of why he’s so successful. “I feel magic mushrooms helped me improve as a human being. It also made me more creative, open and innovative. It made me a better entrepreneur and investor,” he states.
